Opus Genetics (IRD)

• Market cap: $328M
• 1 day: -2.7%
• 5 days: 2.32%
• 1 month: -2.93%
• 3 months: -11.97%
• 6 months: 94.61%
• Year to date: 87.26%
• 1 year: 329.89%
• 5 years: -18.48%
• 10 years: -96.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Employees: 28